Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.
LC-MS
PC3 cells
carbonic anhydrase I
exosomes
malignant potential
siCA1
siMock
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
09
01
2019
revised:
14
02
2019
accepted:
26
02
2019
pubmed:
28
3
2019
medline:
21
7
2020
entrez:
28
3
2019
Statut:
ppublish
Résumé
We report results showing that the silencing of carbonic anhydrase I (siCA1) in prostatic (PC3) tumour cells has a significant impact on exosome formation. An increased diameter, concentration and diversity of the produced exosomes were noticed as a consequence of this knock-down. The protein composition of the exosomes' cargo was also altered. Liquid chromatography and mass spectrometry analyses identified 42 proteins significantly altered in PC3 siCA1 exosomes compared with controls. The affected proteins are mainly involved in metabolic processes, biogenesis, cell component organization and defense/immunity. Interestingly, almost all of them have been described as 'enhancers' of tumour development through the promotion of cell proliferation, migration and invasion. Thus, our results indicate that the reduced expression of the CA1 protein enhances the malignant potential of PC3 cells.
Identifiants
pubmed: 30916466
doi: 10.1111/jcmm.14265
pmc: PMC6484292
doi:
Substances chimiques
Carbonic Anhydrase I
EC 4.2.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3641-3655Informations de copyright
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Références
J Cell Mol Med. 2017 Mar;21(3):543-551
pubmed: 27704726
Cancer Genomics Proteomics. 2017 01-02;14(1):1-15
pubmed: 28031234
Cold Spring Harb Perspect Biol. 2013 Feb 01;5(2):
pubmed: 22767671
Oncotarget. 2017 May 16;8(20):32833-32847
pubmed: 28427184
Medicine (Baltimore). 2017 May;96(19):e6865
pubmed: 28489783
Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215
pubmed: 27686597
Med Res Rev. 2003 Mar;23(2):146-89
pubmed: 12500287
J Neurooncol. 2010 Aug;99(1):13-24
pubmed: 20063114
Am J Cancer Res. 2015 Aug 15;5(9):2756-76
pubmed: 26609482
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
Tissue Cell. 2018 Apr;51:39-48
pubmed: 29622086
Trends Biochem Sci. 2006 Mar;31(3):164-72
pubmed: 16483782
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
FEBS Lett. 2014 Aug 19;588(16):2685-92
pubmed: 24747424
Oncogene. 2000 Mar 9;19(11):1419-27
pubmed: 10723133
Mol Cancer. 2010 Jul 28;9:200
pubmed: 20667089
Neoplasma. 2008;55(6):488-92
pubmed: 18999876
Tumour Biol. 2016 Jan;37(1):553-9
pubmed: 26232327
Br J Cancer. 2009 May 19;100(10):1603-7
pubmed: 19401683
PLoS One. 2014 Sep 30;9(9):e108925
pubmed: 25268476
Cell Mol Life Sci. 2014 Feb;71(3):379-404
pubmed: 23652611
Genes Cancer. 2010 Aug;1(8):812-21
pubmed: 21779467
Cancer Res. 2005 Jul 1;65(13):5599-606
pubmed: 15994932
Tumour Biol. 2016 Jan;37(1):661-72
pubmed: 26242264
Pathol Oncol Res. 2018 Oct;24(4):885-890
pubmed: 28913610
Methods Mol Biol. 2007;369:107-42
pubmed: 17656749
J Cell Mol Med. 2019 May;23(5):3641-3655
pubmed: 30916466
Expert Opin Ther Targets. 2012 May;16(5):515-23
pubmed: 22512284
ISRN Oncol. 2012;2012:768190
pubmed: 23213568
J Electron Microsc Tech. 1990 Nov;16(3):235-9
pubmed: 2243279
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
J Hematol Oncol. 2015 Jul 10;8:83
pubmed: 26156517
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
J Cell Mol Med. 2018 Jan;22(1):695-699
pubmed: 28782909
Int J Oncol. 2014 May;44(5):1461-9
pubmed: 24589652
Oncotarget. 2016 Jul 5;7(27):41186-41202
pubmed: 27172792
Cancer Invest. 2014 Aug;32(7):330-8
pubmed: 24884829
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Biochem Biophys Res Commun. 2016 Sep 23;478(3):1189-97
pubmed: 27568288
EMBO J. 1994 Aug 1;13(15):3438-47
pubmed: 8062820
BMC Biochem. 2007 Nov 22;8 Suppl 1:S3
pubmed: 18047740
Nanomedicine (Lond). 2016 Feb;11(4):421-37
pubmed: 26784674
Gastroenterology. 1993 Sep;105(3):820-6
pubmed: 8359652
J Biol Chem. 2002 Sep 27;277(39):36570-6
pubmed: 12119296
Mol Cell Biol. 2007 Nov;27(21):7381-93
pubmed: 17785433
J Exp Clin Cancer Res. 2018 Sep 14;37(1):226
pubmed: 30217217
Clin Biochem. 1997 Dec;30(8):613-8
pubmed: 9455614
Cancer Discov. 2017 Jan;7(1):20-37
pubmed: 28003236
Biochem Soc Trans. 2007 Feb;35(Pt 1):12-7
pubmed: 17212580
Br J Pharmacol. 2014 Dec;171(24):5507-23
pubmed: 24665826
Biochem Genet. 2007 Jun;45(5-6):431-9
pubmed: 17464559
ACS Nano. 2016 Apr 26;10(4):3886-99
pubmed: 26978483
Gene. 2018 Mar 10;646:195-202
pubmed: 29305973
Leukemia. 2007 May;21(5):1026-34
pubmed: 17330099
Mol Med Rep. 2014 Aug;10(2):811-7
pubmed: 24819254
Am J Clin Exp Urol. 2015 Apr 25;3(1):1-12
pubmed: 26069882
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812